Corporation announced today it will present data from three
preclinical studies at the 8th
Annual International Respiratory Syncytial Virus (RSV) Symposium
taking place from Sept. 27-30 in Santa Fe, N.M.
The following presentations will occur on Friday, Sept. 28 at 9:30 -
10:30 a.m. Mountain Time:
Poster Presentation 51: "Whole virus RSV vaccine induced protective
immunity with reduced lung histopathology compared to recombinant F
protein RSV vaccine."
Poster Presentation 49: "Intranasal and Intramuscular Routes of RSV
Vaccine Administration Serve to Highlight the Role of Th2 and Th17 in a
Mouse RSV Challenge Model."
Poster Presentation 45: "Immunogenicity and efficacy of Line 19 RSV
vaccine in cotton rats."
During the presentations, NanoBio will share preclinical data on its
nanoemulsion adjuvanted intranasal RSV vaccine which:
Demonstrated improved viral clearance and reduced histopathology in an
RSV mouse challenge model.
Resulted in viral clearance from the lung associated with Th17
generation that is highly correlated with lower airway
Generated robust immune responses that are protective against a
heterologous A2 challenge in cotton rats.
NanoBio's RSV vaccine uses nanoemulsion technology as an intranasal
adjuvant and delivery system derived from its clinically-validated
NanoStat® technology platform.
Source: NanoBio Corporation